No Data
No Data
北海康成-B:2023 年報
Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials
Canbridge Pharmaceuticals (HKG:1228) announced that it would discontinue the development of its new glioblastoma multiforme drug CAN008 after Phase II clinical trials, according to a Monday filing on
Beihai Kangcheng-B (01228) decided to discontinue development and further testing of CAN008 in the field of glioblastoma
Beihai Kangcheng-B (01228) announced that CAN008 in patients newly diagnosed with glioblastoma based on treatment...
Beihai Kangcheng-B (01228) grants 2.7 million share options and 2.7 million restricted share units
Beihai Kangcheng-B (01228) issued an announcement. On April 9, 2024, the company purchased after sales in accordance with the initial public development...
Revenues Working Against CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Following 27% Dive
To the annoyance of some shareholders, CANbridge Pharmaceuticals Inc. (HKG:1228) shares are down a considerable 27% in the last month, which continues a horrid run for the company. For any long-ter
Beihai Kangcheng-B (01228) announced annual results. Shareholders' losses amounted to 379 million yuan, a year-on-year decrease of 21.64%
Beihai Kangcheng-B (01228) announced results for the year ended December 31, 2023, with revenue of 103 million...
No Data